The Cigna Group (CI)

Total revenue exceeded $230B in 2025, growing ~14% year-over-year driven by Evernorth pharmacy volume and Accredo specialty pharmacy. This outpaces UNH's ~10% and CVS Aetna's ~8% growth. The growth is heavily concentrated in pharmacy pass-through revenue which inflates the topline, but even adjusting for that, underlying growth is solid at 7-8%.

Express Scripts remains the #2 PBM behind CVS Caremark, processing 1.4B+ scripts annually. Accredo is the #1 specialty pharmacy by revenue. Cigna Healthcare's commercial business serves 19M+ members with stable-to-growing market share in employer-sponsored insurance. The exit from individual Medicare Advantage refocuses resources on segments where Cigna has genuine competitive advantages.

PBM pricing is under scrutiny but Cigna has demonstrated ability to pass through drug cost increases and negotiate favorable manufacturer rebates. Commercial insurance premiums are rising 7-9% annually, well above medical cost trends. The specialty pharmacy business has strong pricing power given the complexity of administering biologics and gene therapies.

Evernorth's virtual care platform, CareHub analytics, and biosimilar adoption programs represent genuine innovation in healthcare services. The integration of behavioral health, pharmacy, and care delivery into a unified platform is differentiated. However, the pace of technology adoption across the enterprise remains slower than pure-play health tech companies.

Employer health plan switching is a 12-18 month process involving benefits consultants, employee communication, and network adequacy reviews. PBM contracts typically run 3-5 years with significant integration into employer HR and benefits systems. Once Evernorth's specialty pharmacy manages a patient's complex therapy, switching is medically risky and administratively burdensome.

The PBM business has modest network effects — more covered lives give Express Scripts more negotiating leverage with drug manufacturers, which produces better pricing, which attracts more clients. The provider network creates geographic density effects in commercial insurance. But these are scale advantages more than true network effects.

PBM regulation is the biggest moat risk. Congressional proposals to ban spread pricing, mandate rebate pass-throughs, and increase PBM transparency could materially impact Evernorth's economics. State-level PBM reforms are proliferating. Cigna's healthcare licenses and accreditations provide some regulatory moat, but the political environment is hostile to PBM business models.

Cigna's asset-light services model generates strong free cash flow — $10B+ annually with minimal capex requirements. The PBM and insurance businesses require regulatory capital but not heavy physical infrastructure. This allows aggressive capital return via buybacks ($10B+ annually) while maintaining investment in Evernorth platform capabilities.

EPS estimates have been modestly positive over the past 6 months, with 2026 consensus around $30+, implying ~12% growth. Cigna has consistently beaten quarterly estimates by 3-5%. The revision trend is favorable but muted by PBM regulatory uncertainty that keeps analysts from getting too bullish.

The dominant narrative is PBM regulatory risk and managed care political headwinds, amplified by the 2025 shooting tragedy's aftermath on healthcare executive sentiment. Counter-narratives around Evernorth's growth and Cigna's discounted valuation exist but struggle to gain traction. The failed Humana merger created some strategic uncertainty that has since resolved.

CEO David Cordani has been a steady hand, executing the Evernorth transformation and maintaining disciplined capital allocation. Buybacks have been aggressive and well-timed, reducing share count meaningfully. The decision to walk away from the Humana deal showed capital discipline. Management's 10-15% EPS growth target is credible given current trajectory.